<![CDATA[Selinexor Misses PFS End Point in TP53 Wild-Type Endometrial Cancer]]>
Phase 3negativeSelinexorNegative
AI Analysis
Summary
Selinexor failed to significantly improve progression-free survival versus placebo in a Phase 3 trial for TP53 wild-type advanced or recurrent endometrial cancer. The negative trial result represents a significant setback for the drug's development in this indication.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Selinexor maintenance therapy did not significantly improve PFS vs placebo in TP53 wild-type advanced or recurrent endometrial cancer
Importance:8/10
Sentiment:
-0.80
Phase 3endometrial cancernegative dataPFSmaintenance therapy
Related Companies
Read the original article
Published by Cancer Network on July 31, 2026 2:30 PM